title: The effects of drug metabolism inducers on the delayed neurotoxicity and disposition of tri-o-cresyl phosphate in hens following a single intravenous administration.
abstract: Intravenous (iv) administration of tri-o-cresyl phosphate (TOCP) caused a delayed neurotoxic effect in hens similar to that produced by oral and dermal administration. The iv ED50s for producing ataxia and paralysis were estimated to be 15.9 mg/kg and 31.7 mg/kg respectively. The tissue disposition of unaltered TOCP was determined in hens following a single iv injection of 40 mg/kg of TOCP. One hour (hr) after the injection, the leg muscle contained the highest concentration, 26.99 micrograms/g fresh weight followed by the adipose tissue. Among the nerve tissues, the sciatic nerve had the highest concentration, 9.63 micrograms/g followed by the spinal cord and the brain. Except the adipose tissue and the sciatic nerve, the concentration in all analyzed tissues dropped below 1.0 microgram/g (ml) after 24 hr. An unidentified metabolite appeared in bile taken 1 and 3 hr after the injection. Pretreatment of hens with 3-methylcolathrene (3-MC) and beta-naphthoflavone (B-NF) protected against the TOCP-induced delayed neurotoxicity, whereas phenobarbital (PB) failed to protect against the neurotoxicity. Plasma creatine phosphokinase (CK) activity in paralytic birds increased approximately 4 times of the control or symptomless hens on the 21st day. 3-MC-, B-NF- and PB-treatment depressed substantially the concentration of unaltered TOCP in brain and plasma 1 hr after iv dosing with 40 mg/kg of TOCP. Only B-NF pretreatment lowered the level of TOCP in spinal cord. There was no effect of these inducers on the level of TOCP in sciatic nerve and adipose tissue. B-NF and 3-MC lowered significantly the TOCP level in leg muscle, whereas PB had no such effect. More attention should be paid to the role of TOCP in muscle, especially to the leg muscle, judging from the present toxicological and metabolic studies.
authors.affiliation: Department of Public Health, Fukushima Medical College, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Konno
authors.forename: K
authors.initials: K
authors.lastname: Katoh
authors.forename: T
authors.initials: T
authors.lastname: Yamauchi
authors.forename: M
authors.initials: M
authors.lastname: Fukushima
mesh_terms: D000818:Animals; D001259:Ataxia / Q000139:chemically induced / Q000517:prevention & control; D001571:Benzoflavones / Q000494:pharmacology*; D001711:Biotransformation / Q000187:drug effects; D002645:Chickens; D003408:Cresols / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D007275:Injections, Intravenous; D008748:Methylcholanthrene / Q000494:pharmacology*; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010243:Paralysis / Q000139:chemically induced / Q000517:prevention & control; D013997:Time Factors; D014018:Tissue Distribution / Q000187:drug effects; D014317:Tritolyl Phosphates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D019324:beta-Naphthoflavone
chemical_list: D001571:Benzoflavones; D003408:Cresols; D005419:Flavonoids; D014317:Tritolyl Phosphates; D008748:Methylcholanthrene; D019324:beta-Naphthoflavone